PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50119C00054 — EO14042 - THE ADVANCEMENT OF THE DEVELOPMENT OF A SMALLPOX BIODEFENSE THERAPEUTIC TO THE CLINICAL STAGE AS AN ANTIBODY-…

EO14042 - THE ADVANCEMENT OF THE DEVELOPMENT OF A SMALLPOX BIODEFENSE THERAPEUTIC TO THE CLINICAL STAGE AS AN ANTIBODY-… is a federal NONE award for Department of Health and Human Services (HHS) held by BIOFACTURA, INC.. Estimated value $65.8M ($43.3M obligated). Current period of performance ends Mar 30, 2029. Last award drew 1 bidder. Place of performance: FREDERICK, MD.

$65.8M
Estimated Value
$43.3M
Obligated
Mar 30, 2029
PoP End / Expires
1
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

BIOFACTURA, INC. holds $24.0M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Mar 30, 2029 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75A50119C00054
AgencyDepartment of Health and Human Services (HHS)
IncumbentBIOFACTURA, INC.
UEIC1ZWQAYK4J58
NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN41
Place of performanceFREDERICK, MD
PoP end (current)Mar 30, 2029
Obligated$43.3M

EO14042 - THE ADVANCEMENT OF THE DEVELOPMENT OF A SMALLPOX BIODEFENSE THERAPEUTIC TO THE CLINICAL STAGE AS AN ANTIBODY-BASED COUNTERMEASURE

Recompete timing

Public
Expiring in 956 days

Current PoP ends Mar 30, 2029 (956 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Sep 30, 2027.

Watch this contract — one email →

Incumbent footprint

Public record

BIOFACTURA, INC.$24.0M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$24.0M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open BIOFACTURA, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50119C00054?

75A50119C00054 (EO14042 - THE ADVANCEMENT OF THE DEVELOPMENT OF A SMALLPOX BIODEFENSE THERAPEUTIC TO THE CLINICAL STAGE AS AN ANTIBODY-…) is a Department of Health and Human Services (HHS) award with an estimated value of $65.8M, currently held by BIOFACTURA, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50119C00054?

BIOFACTURA, INC. is the incumbent with $24.0M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Mar 30, 2029.

When does 75A50119C00054 come up for recompete?

SCOUT tracks a period-of-performance end of Mar 30, 2029. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50119C00054